Cutting-edge yacht and electric catamaran designer Sunreef Yachts has unveiled its latest generation of solar skin technology. The silicon ...

Following CORDStrom TM, INmune Bio plans to transition production of INKmune ®, its NK-priming cell medicine for solid tumors, to the same facility, supporting ongoing and future trials in the US and ...

The BSA developed by Hyundai Mobis consists of a battery management system (BMS), hardware consisting of a fire extinguishing ...

Trump confirms tariffs remain on electronics amid exemptions. Upcoming investigations may target semiconductors & supply ...

Early-onset CRC (EO-CRC) was associated with Flavonifractor plautii and increased bile acid, tryptophan, and choline ...

Four leading companies CTMC, Iovance Therapeutics, KSQ, and TILT Biotherapeutics prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities.

By mapping the subcellular architecture and protein interactions within cells, researchers can better understand how mutations contribute to pediatric cancers and other conditions.